Deanxit can improve the dizziness, anxiety, and quality of life of patients with chronic subjective dizziness

Objective: This study was designed to analyze the clinical effectiveness of Deanxit (DEA) for treating chronic subjective dizziness (CSD). Methods: A total of 110 CSD patients (all from a community survey) admitted to our hospital from August 2018 to August 2020 were recruited as the study cohort. Among them, 60 who underwent DEA treatment were placed in the research group (RG) and 50 who underwent basic treatment were placed in the control group (CG). The two groups' efficacy, their dizziness disability rating scale (DHI) scores, the improvement in their clinical symptoms (duration of dizziness, frequency of dizziness attacks), their anxiety and depression (i.e., their Hamilton Anxiety Scale (HAMA) scores) and their Hamilton Depression Scale (HAMD)) scores, their sleep quality and their quality of life (short form 36 (SF-36) health survey scores) were observed and compared. Results: Compared with the CG, the DHI scores, the dizziness durations, the number of dizziness attacks and the HAMA and HAMD scores in the RG were markedly lower than they were in the CG, and the sleep quality levels and SF-36 scores were higher than they were in the CG. Conclusion: DEA treatment helps to improve the dizziness, anxiety, and quality of life of CSD patients.